KEY POINTS
- This prospective single-center phase II trial from Udine, Italy, enrolled 70 patients with early-stage breast cancer at increased risk of local recurrence between March 2022 and October 2024. Eligibility required at least one high-risk feature, including age ≤50 years, triple-negative phenotype, grade 3 disease, or positive/close surgical margins. Median age was 48 years, median tumor size was 12 mm, and 90% were node-negative. Median follow-up was 30.9 months (IQR 18.7–39.1).
- All patients underwent breast-conserving surgery followed by a single-fraction 7.5-Gy stereotactic boost using GammaPod, administered before whole-breast irradiation of 40.05 Gy in 15 fractions. The GammaPod system used vacuum-assisted breast immobilization and image-guided stereotactic treatment. CTV included the surgical cavity plus a 10-mm margin, modified near skin and adjacent structures, followed by a 3-mm PTV expansion. Median PTV was 35.6 cm³, and median stereotactic treatment delivery time was 15.4 minutes.
- Acute toxicity was generally mild, although one grade 3 dermatitis event occurred. At three months, dermatitis affected 12/70 patients (17%), including one grade 2 and one grade 3 event (1.4% each). Pain occurred in 10%, and dyschromia in 12%, predominantly grade 1–2. No grade 4 toxicity was reported. These outcomes describe the entire treatment sequence, including subsequent whole-breast irradiation, and do not isolate the contribution of the GammaPod boost.
- Moderate or severe late toxicity was uncommon during available follow-up. Five patients (7%) developed grade 2 fibrosis within 18 months, while no grade ≥3 late toxicity was observed. At six months, fibrosis affected 24%, mostly grade 1, declining to 17% at 12 months and 9.5% at 24 months, all grade 1 among those assessed at the final time point. However, the 24-month toxicity evaluation included only 42/70 patients (60%), limiting confidence in the apparent decline over time.
- Early disease control was favorable but remains preliminary. At 24 months, the reported local recurrence rate was 1.5%, while regional recurrence was 0% at that assessment. The manuscript describes one patient with local and locoregional recurrence during follow-up, but provides limited event-level detail. These observations do not establish comparative tumor control, particularly because the study was designed primarily around toxicity rather than powered oncological efficacy.
- The phase II design specifically examined clinically relevant fibrosis risk. The sample-size calculation targeted a two-year grade ≥2 toxicity rate of 13% or lower, with a rate of 25% or higher considered unacceptable. Although the observed cumulative grade 2 fibrosis frequency was low, the investigators did not demonstrate equivalence or noninferiority to standard sequential boost or simultaneous integrated boost regimens. The technique also required specialized GammaPod hardware, and seven patients were excluded during pre-enrollment fitting because no suitable immobilization cup was available.
- The absence of a randomized comparator and incomplete late follow-up remain important limitations. Longer observation is required to establish the full incidence of fibrosis, fat necrosis, cosmetic deterioration, and late recurrence, particularly after large single-fraction doses. The study did not include a standard boost control group, and no comprehensive comparative cosmetic or patient-reported quality-of-life analysis was presented. Its findings therefore establish early tolerability and technical feasibility rather than a preferred boost prescription.
CLINICAL TAKEAWAY
A single 7.5-Gy GammaPod tumor-bed boost before hypofractionated whole-breast irradiation was feasible and associated with relatively low observed moderate late toxicity in selected high-risk early breast cancer patients. However, one grade 3 acute dermatitis event occurred, and only 60% of patients had evaluable toxicity data at 24 months. Randomized comparison and longer-term assessment of fibrosis, cosmesis, and local control are needed before this strategy can replace conventional boost approaches.